Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a
larger class of compounds that inhibit histone deacetylases (HDAC).
Results of animal studies indicate that vorinostat crosses the placenta and is
found in fetal plasma at levels up to 50% of maternal concentrations. Doses.
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in
people whose disease has not improved, has gotten worse, or has come back ...
Jul 3, 2013 ... On October 6, 2006, the U.S. Food and Drug Administration granted approval to
vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase ...
Dec 12, 2006 ... The HDAC inhibitor vorinostat (suberoylanilide hydroxamic acid or SAHA) blocks
cancer cell proliferation both in vitro and in vivo with little or ...
Dec 10, 2015 ... Vorinostat is in a class of anti-cancer therapies called histone deacetylase (
HDAC) inhibitors. Histone deacetylation is a biochemical process ...
Structure of vorinostat (suberoylanilide hydroxamic acid, SAHA). Phase I
vorinostat clinical trials were initiated with both an i.v. and an oral drug
formulation [2, 6, ...
Zolinza (vorinostat) is used to treat skin problems caused by cutaneous T-cell
lymphoma. Zolinza is usually given after other treatments have been tried without
Easy to read patient leaflet for vorinostat. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Vorinostat (suberoylanilide hydroxamic acid; Zolinza®;. Merck; Whitehouse
Station,. USA) also known as SAHA, is a competitive oral inhibitor. (HDAC-i) of